These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17555471)

  • 41. Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.
    Martello M; Poletti A; Borsi E; Solli V; Dozza L; Barbato S; Zamagni E; Tacchetti P; Pantani L; Mancuso K; Vigliotta I; Rizzello I; Rocchi S; Armuzzi S; Testoni N; Marzocchi G; Martinelli G; Cavo M; Terragna C
    Blood Cancer J; 2022 Jan; 12(1):15. PubMed ID: 35082295
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Intracranial involvement in newly diagnosed multiple myeloma with TP53 deletion: Two case reports].
    Qu S; Liao L; Xie Y; Zheng Z; Chen B
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Nov; 43(11):1272-1275. PubMed ID: 30643076
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations.
    Peterson JF; Rowsey RA; Marcou CA; Pearce KE; Williamson CM; Frederick LA; Greipp PT; Ketterling RP; Kumar S; Viswanatha DS; Polley MY; Fink JM; Reichard KK; Van Dyke DL; Baughn LB
    Blood Cancer J; 2019 Feb; 9(3):20. PubMed ID: 30783078
    [No Abstract]   [Full Text] [Related]  

  • 45. Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma: relationship to proliferative activity and prognostic significance.
    Markovic O; Marisavljevic D; Cemerikic V; Suvajdzic N; Milic N; Colovic M
    Med Oncol; 2004; 21(1):73-80. PubMed ID: 15034217
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hierarchy of mono- and biallelic
    Munawar U; Rasche L; Müller N; Vogt C; Da-Via M; Haertle L; Arampatzi P; Dietrich S; Roth M; Garitano-Trojaola A; Steinhardt MJ; Strifler S; Gallardo M; Martinez-Lopez J; Bargou RC; Heckel T; Einsele H; Stühmer T; Kortüm KM; Barrio S
    Blood; 2019 Sep; 134(10):836-840. PubMed ID: 31340981
    [No Abstract]   [Full Text] [Related]  

  • 47. [Clinical implications and prognostic value of TP53 gene mutation and deletion in patients with myelodysplastic syndromes].
    Huang HJ; Shi ZX; Li B; Qin TJ; Xu ZF; Zhang HL; Fang LW; Hu NB; Pan LJ; Qu SQ; Liu D; Cai YN; Zhang YD; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):215-221. PubMed ID: 30929389
    [No Abstract]   [Full Text] [Related]  

  • 48. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia.
    Thornton PD; Gruszka-Westwood AM; Hamoudi RA; Atkinson S; Kaczmarek P; Morilla RM; Hilditch BL; A'Hern R; Matutes E; Catovsky D
    Hematol J; 2004; 5(1):47-54. PubMed ID: 14745430
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognosis, Biology, and Targeting of
    Flynt E; Bisht K; Sridharan V; Ortiz M; Towfic F; Thakurta A
    Cells; 2020 Jan; 9(2):. PubMed ID: 31991614
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma.
    Feng X; Guo J; An G; Wu Y; Liu Z; Meng B; He N; Zhao X; Chen S; Zhu Y; Xia J; Li X; Yu Z; Li R; Ren G; Chen J; Wu M; He Y; Qiu L; Zhou J; Zhou W
    Adv Sci (Weinh); 2022 Mar; 9(9):e2104491. PubMed ID: 35088582
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation.
    Rudenko HC; Else M; Dearden C; Brito-Babapulle V; Jones C; Dexter T; Fenwick K; Mackay A; Ashworth A; Matutes E; Gonzalez D; Catovsky D; Morgan GJ
    Leuk Lymphoma; 2008 Oct; 49(10):1879-86. PubMed ID: 18949611
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
    Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
    Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The clinical characteristics and prognosis of IGH deletion in multiple myeloma.
    He H; Fu W; Jiang H; Du J; Zhou L; Zhang C; Xi H; Li R; Hou J
    Leuk Res; 2015 May; 39(5):515-9. PubMed ID: 25817540
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Significance of
    Ye F; Wang T; Liu A; Li Y; Li N; Wang H; Chen W
    Turk J Haematol; 2021 Dec; 38(4):246-253. PubMed ID: 33938208
    [TBL] [Abstract][Full Text] [Related]  

  • 56. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
    Corre J; Perrot A; Caillot D; Belhadj K; Hulin C; Leleu X; Mohty M; Facon T; Buisson L; Do Souto L; Lannes R; Dufrechou S; Prade N; Orsini-Piocelle F; Voillat L; Jaccard A; Karlin L; Macro M; Brechignac S; Dib M; Sanhes L; Fontan J; Clement-Filliatre L; Marolleau JP; Minvielle S; Moreau P; Avet-Loiseau H
    Blood; 2021 Mar; 137(9):1192-1195. PubMed ID: 33080624
    [TBL] [Abstract][Full Text] [Related]  

  • 57. p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma.
    Sheth N; Yeung J; Chang H
    Leuk Res; 2009 Oct; 33(10):1357-60. PubMed ID: 19201468
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma.
    Lavarino C; Corletto V; Mezzelani A; Della Torre G; Bartoli C; Riva C; Pierotti MA; Rilke F; Pilotti S
    Br J Cancer; 1998; 77(1):125-30. PubMed ID: 9459157
    [TBL] [Abstract][Full Text] [Related]  

  • 59. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinical Efficacy and Prognosis of Double-Hit Multiple Myeloma Patients with Deletion P53 Treated with Regimen Based on Bortezomib].
    Wang DM; Chen YY; Meng Z; Zhang YX; Guo SQ; Li YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1221-1227. PubMed ID: 32798402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.